Veterinary World

     Open access and peer reviewed journal  

ISSN (Online): 2231-0916

ISSN (Print): 0972-8988

 

Home l Editorial board l Instructions for authors l Reviewer guideline l Open access policy l Archives l FAQ


Open Access

Copyright: The authors. This article is an open access article licensed under the terms of the Creative Commons Attribution License

(http://creativecommons.org/licenses/by/2.0) which permits unrestricted use, distribution and reproduction in any medium, provided the work is properly cited.


Research (Published online: 07-11-2014)

4. Tracing the antibody mediated acquired immunity by Foot and Mouth disease and Rift Valley Fever combined vaccine in pregnant ewes and their lambs - Wael Mossad Gamal, Eman Mahmoud Mohamed Soliman and Mona Ali El-Manzalawy

Veterinary World, 7(11): 922-928

 

 

   doi: 10.14202/vetworld.2014.922-928

 

 

Wael Mossad Gamal: Department of Foot and Mouth disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt; waelmossad@gmail.com

Eman Mahmoud Mohamed Soliman: Department of reference strain bank, Central Laboratory for Evaluation of Veterinary Biologics, Cairo, Egypt; emansoliman80@gmail.com

Mona Ali El-Manzalawy: Department of Rift Valley Fever, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt; elmanzalawy1970@gmail.com

 

Received: 15-07-2014, Revised: 19-09-2014, Accepted: 26-09-2014, Published online: 07-11-2014

 

Corresponding author: Wael Mossad Gamal, e-mail: waelmossad@gmail.com



Aim: The aim of this study was to provide adequate protection to ewes and their lambs against Foot and Mouth disease (FMD) and Rift Valley Fever (RVF).

Materials and Methods: A combined inactivated oil vaccine was prepared successfully. Such vaccine was found to be free from foreign contaminants, safe and potent as determined by quality control tests such as challenge protection percentage for FMD and mice ED50 for RVF. Vaccination of pregnant ewes with the prepared combined vaccine and determination of the antibody level via serum neutralization test (SNT) and Enzyme Linked immune sorbent assay (ELISA) in the vaccinated pregnant ewes and their lambs.

Results: Vaccination of pregnant ewes revealed that these ewes exhibited high levels of specific antibodies against the included vaccine antigens (Foot and Mouth disease virus type A Iran O5, O PanAsia and SAT2/EGY/2012 and RVFV-ZH501). FMD antibodies recorded their peaks by the 10th week while those of RVF recorded their peaks by the 12th week post vaccination then all antibodies began to decrease gradually to reach their lowest protective titers for FMD by the 32nd week post vaccination and those for RVF by the 34th week post vaccination. Potency test of the prepared combined vaccine expressed as protection percentage of vaccinated sheep against target virulent FMD virus serotypes reflected a protection percentage of 80% against type O and SAT2 and 100% against A while for RVF, the mice ED50 was found to be 0.009 indicating the potency of the prepared vaccine. The antibody titer in serum and colostrum of vaccinated pregnant ewes at day of parturition (10-12 week post vaccination) recorded a high titer against FMD serotype (O), serotype (A), serotype (SAT2) and against RVF. It was noticed that the colostrum antibody titers were slightly higher than those in the sera of vaccinated ewes at time of parturition. The newly born lambs from vaccinated ewes, exhibited good levels of maternal immunity against the included antigens through suckling their mother colostrum by the 24 hrs. post parturition. The newly born lambs recorded their highest level by 1 week of birth and lasted within a protective level up to 11-12 week of birth.

Conclusion: Using of FMD/RVF combined vaccine provided a sufficient immune status for pregnant ewes as well as for their lambs. Vaccination of newly born lambs should be carried out by the 4th month of birth.

Keywords: FMD, RVF, combined vaccine, pregnant ewes, new born lambs, SNT, ELISA.



1. Depa, P.M., Dimri, U., Sharma, M.C. and Tiwari, R. (2012) Update on epidemiology and control of foot and mouth disease - A menace to international trade and global animal enterprise. Vet. World, 5(11): 694-704.
http://dx.doi.org/10.5455/vetworld.2012.693-703
 
2. Longjam, N., Deb, R., Sarmah, A.K., Tayo, T., Awachat, V.B. and Saxena, V.K. (2011) A brief review on diagnosis of foot-and-mouth disease of livestock: Conventional to molecular tools. Vet. Med. Int., 2011: 905768.
http://dx.doi.org/10.4061/2011/905768
PMid:21776357 PMCid:PMC3135314
 
3. Aidaros, H.A. (2002) Regional status and approaches to control and eradication of FMD in the middle east and North Africa. Rev. Sci. Tech. Off. Int. Epizoot., 21(3): 451-8.
 
4. Farag, M.A., Aggour M.A. and Daoud, A.M. (2005) ELISA as a rapid method for detecting the correlation between the field isolates of foot and mouth disease and the current used vaccine strain in Egypt. Vet. Med. J., Giza., 53(4): 949-955.
 
5. Satya, P. (2009) Vaccination against foot‑and‑mouth disease virus: Strategies and effectiveness. Expert Rev. Vaccines, 8(3): 347-365.
http://dx.doi.org/10.1586/14760584.8.3.347
PMid:19249976
 
6. Abed El- Rahman, A.O., Farag, M.A., El- Kilany, S., Ali, S.M. and Yazed, M.A. (2006) Isolation and identification of serotype O of foot and mouth disease virus from imported Bulls and its correlation to the current used vaccine strain O1/3/1993. Proc. 3rd International Conference Veterinary Research Division. NRC, Cairo, Egypt, p91-100.
 
7. Shawky, M., Abd El-Aty, M., Fakry, H.M., Daoud, H.M., El-Sayed, I.E., Mossad, G.W., Rizk S.A., Abu-Elnaga, H., Mohamed, A.A., Abd El-Kreem A. and Farouk, E. M. (2013) Isolation and molecular characterization of foot and mouth disease SAT2 virus during outbreak 2012 in Egypt. J. Vet. Adv., 3(2): 60-68.
http://dx.doi.org/10.5455/jva.20130219104353
 
8. OIE. (2013) OIE Raift Valley Fever Factsheet. Accessed on 21-06-2013 .
 
9. Mirabela, R., Richard, B., Michael, R.H., Stanley, J.W., Stefan, B., Willy, W. and Alexander, N.F. (2012) An assembly model of rift valley fever virus. Front Microbial, 3: 254.
 
10. WHO. (2012) Rift Valley Fever. Fact Sheet. No 207.
 
11. Hanafi, A.H., Fryauff, D.J., Saad, M.D., Soliman, A.K., Mohareb, E.W., Medhat, I., Zayed, A.B., Szumlas, D.E., Earhart, K.C., (2011) Virus isolation sand high population density implicate culex antennatus (Becker) (Diptera: Culicidae) as avector of rift valley fever virus during an outbreak in the Nile Delta of Egypt. Acta Trop., 119(2011): 119-124.
http://dx.doi.org/10.1016/j.actatropica.2011.04.018
PMid:21570939
 
12. Summerpa, S.K., Clarence, J.P., James, L., Eric, M.M., Samuel, M., Kariuki Njenga, M., Robert, F.B., Clinton White, A.J.R. and Charles, H.K. (2010) Sever rift valley fever may present with a characteristic clinical syndrome. Am. J. Trop. Med. Hyg., 82(3): 371-375.
http://dx.doi.org/10.4269/ajtmh.2010.09-0669
PMid:20207858 PMCid:PMC2829894
 
13. Lombard, M., Pastoret, P.P. and Moulin, A.M. (2007) A brief of vaccines and vaccination. Rev. Sci. Tech., 26(1): 29-48.
PMid:17633292
 
14. Sonia, A.M. (2003) Comparative studies on immune response of FMD and RVF combined vaccine containing OIMS 1313 oil adjuvant. M. V. Sc. Thesis, Microb. Faculty of Veterinary Medicine, Alexandria University, Egypt.
 
15. Ragaa, A.E (2007) Studies on production of oil inactivated rift valley fever vaccine using Montanide (IMS). M. Vet. Sic Thesis, (Infectious). Faculty of Veterinary Medicine. El Monufia University.
 
16. Postema, A.S., Myers, M.G. and Breiman, R.F. (2001) Challenges in the development, licensure, and use of combination vaccines. Clin, Infect. Dis., 33: S261-S266.
http://dx.doi.org/10.1086/322560
PMid:11709757
 
17. Falk, L.A., Arciniega, J., and McVittie, L. (2001) Manufacturing issues with combining different antigens: A regulatory perspective. Clin. Infect. Dis., 33: S351-S355.
http://dx.doi.org/10.1086/322579
PMid:11709772
 
18. Shabana, W. (2014) Preparation of combined oil vaccine against foot and mouth disease and rift valley fever in sheep. Phd. Faculty of Veterinary Medicine, Cairo University.
 
19. Xuan H., Li Y., Fang, H. and Zheng, C. (2011) Establishment of persistent infection with foot and mouth disease virus in BHK-21 cells. Virol. J., 8: 169.
http://dx.doi.org/10.1186/1743-422X-8-169
PMid:21492421 PMCid:PMC3097150
 
20. Reed, L.J. and Muench, H. (1938) A simple method for estimating fifty percent (50%) end points. Am. J. Hyg., 27: 493-497.
 
21. Health Protection Agency. (2009) Complement fixation tests. Issue no: 3 Issue date 11.12.09 Issued by: Standards unit, Department for Evaluations, standards and Training p1 of 23.
 
22. El Nimr, M.M. (1980) Studies on the inactivated vaccine against rift valley fever. Ph. D. Thesis (Microbiology). Faculty of Veterinary Medicine. Assuit University, Egypt.
 
23. Ismail, A.H., El-Mahdy, S.A., Mossad, W.G., Abd El-Krim, A.S., Abou El-Yazid, M. and Ali, S.M (2013) Optimization of the inactivation process of FMD virus serotype SAT-2 by binary ethyleneimine (BEI). J. Vet, Adv., 3(3): 117-124.
 
24. Code of Federal Regulation of USA. (1986) Animal and Animal Products 9\1986. Office of the Federal Register National Archives and Record Administration, ??? .
 
25. Randall, R., Binn, L.N. and Harrison, V.R. (1964) Immunisation against Rift Valley fever virus. Studies on the immunogenicity of lyophilised formalin inactivated vaccine. J. Immunol., 92: 293-299.
 
26. Ferreira, M.E.V. (1976) Microtitre neutralization test for the study of FMD antibodies. Bol. Cent. Pan. Am. Fiebre Aftosa, 21: 22-23.
 
27. Voller, A., Bidwell, D. and Bartlett, A. (1976) Microplate enzyme immunoassay for the immunodignosis of virus infection. Am. Soc. Microbiol., 506-512.
 
28. Gihan, K. M.; Elian, K. A. and Eman, M. S. (1998): Studies on the keeping quality of binary inactivated Rift Valley fever Vaccine. Assuit Vet. J., 39, (77): 169 179.
 
29. Walker,J.S. (1975): Rift Valley Fever foreign animal disease. Their prevention, diagnosis and control. Committee of foreign animal disease of the United State. Animal Health Assoc., 209-221
 
30. Barteling, S.J. and Vreswij, K.J. (1991) Development in foot and mouth disease vaccine. Vaccine, 9(2): 75-88.
http://dx.doi.org/10.1016/0264-410X(91)90261-4
 
31. Mona, F.M. (2005) Trial for production of highly immunized oily inactivated RVFV vaccine. M. Vet. Sci. thesis (Microbiology). Fac. Vet. Med. Banha University, Egypt.
 
32. Gihan, K.M. (1990) Studies on rift valley fever among animals in Egypt. Ph. D Thesis, Infectious Disease. Faculty of Veterinary Medicine, Zagazig University, Egypt.
 
33. Daoud, A.M., El-Deghaidy, W., Shawky, M., Hassan, K.Z. and Taha, M.M. (2001) Trial for preparation and evaluation of inactivated alhydragel combined vaccine for FMD and RVF. Beni-Suef Vet. Med. J., XI(2): 599-607.
 
34. El-Sayed, E., Mossad, W., Ali, S.M. and Shawky, M. (2012) Studies on the duration of immunity induced in cattle after natural FMD infection and post vaccination with bivalent oil vaccine. Vet. World, 5(10): 603-608.
http://dx.doi.org/10.5455/vetworld.2012.603-608
 
35. El-Shehawy, L.E., Tallat, A.A. and EL-Watany, H.M. (2004) Some studies on maternal immunity of FMD in sheep. J. Egypt. Vet. Med. Assoc. 64(3): 2004.
 
36. ElSayed, N.E. (2013) Recent approach for development of the oil inactivated rift valley fever vaccine using new surfactant blend. M. V. Sc. Thesis Virology. Faculty of Veterinary Medicine, Benha Univerisity.
 
37. El-Sawalhy A.A., Hamoda F.K., Elian K.A., and Gehan M.K. (1997): Clinical and laboratory studies on Rift Valley Fever vaccines in sheep. J. Egypt Vet. Ass; 57(1):363-386.